Yamamura T, et al. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS 2018, abstract 323.
Onderliggende oorzaken TIA en minor stroke beïnvloeden risico ernstig vasculair event
dec 2023 | Atherosclerose, Neuro-vasculair